OpSsens Will Participate and Present at Two Investment Conferences Lytham Partners and Raymond James

Return to news

OPSENS WILL PARTICIPATE AND PRESENT AT TWO INVESTMENT CONFERENCES

Lytham Partners and Raymond James

Quebec City, Quebec, June 9, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company commercializing a  second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that it will present at two investment conferences.

Lytham Partners Summer 2021 Investor Conference, June 14-16

OpSens will be participating in the Lytham Partners Summer 2021 Investor Conference on June 14-16. Louis Laflamme will be presenting on Tuesday, June 15, 2021, at 2:45 p.m. ET.

The webcast will be available on the investor page on www.OpSens.com and on https://www.webcaster4.com/Webcast/Page/2512/41473, on the day and time of the event. The presentation will be afterwards archived and available for replay.

Management will also participate in virtual one-on-one meetings throughout the event. To schedule a meeting, please contact Lytham Partners by email at [email protected]. Investors interested in attending the conference can register here.

Raymond James Human Health Innovations Conference, June 21-23

OpSens will be participating in the Raymond James Human Health Innovations Conference on June 21-23. Louis Laflamme will be presenting on Tuesday, June 22, 2021, at 8:00 a.m. ET.

The webcast will be available on the investor page at www.OpSens.com on the day of the event and afterwards be archived and available for replay.

Management will also participate in virtual one-on-one meetings throughout the event. This conference is by invitation only. To schedule a meeting, please contact your Raymond James representative.

 About OpSens Inc. (www.OpSens.com or OpSensMedical.com)

OpSens focuses mainly on products for cardiology. OpSens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

For information, contact

 Louis Laflamme, CPA, CA, President and Chief Executive Officer or

Robin Villeneuve, CPA, CA, Chief Financial Officer at 418.781.0333

PDF Version